Joseph L. Goldstein | |
---|---|
Born | Joseph Leonard Goldstein [1] April 18, 1940 |
Education | |
Known for | cholesterol |
Awards |
|
Scientific career | |
Fields | Biochemistry |
Institutions | University of Texas Southwestern Medical Center |
Website | profiles |
Joseph Leonard Goldstein ForMemRS (born April 18, 1940) is an American biochemist. He received the Nobel Prize in Physiology or Medicine in 1985, along with fellow University of Texas Southwestern researcher, Michael Brown, for their studies regarding cholesterol. [2] They discovered that human cells have low-density lipoprotein (LDL) receptors that remove cholesterol from the blood and that when LDL receptors are not present in sufficient numbers, individuals develop hypercholesterolemia and become at risk for cholesterol related diseases, notably coronary heart disease. [3] Their studies led to the development of statin drugs. [2]
Goldstein was born in Kingstree, South Carolina, the son of Fannie (Alpert) and Isadore E. Goldstein, who owned a clothing store. His family is Jewish. [4] Goldstein received his BSci from Washington and Lee University in 1962, and his MD from the University of Texas Southwestern Medical School in 1966. [2] Upon completion of his residency, Goldstein moved to the National Institutes of Health (NIH) in Bethesda, Maryland, where he worked in biochemical genetics. [5] In 1972, Goldstein relocated back to the Southwestern Medical Center, accepting a post as the head of the Division of Medical Genetics. [5]
At the Southwestern Medical Center Goldstein collaborated extensively with Michael Brown, a fellow researcher at the center who had also worked at the NIH. [5] From 1973 to 1985, Goldstein and Brown together published over one hundred major papers. [6] They are both listed in Thomson Reuters’ index of highly cited authors. [7] Frequently mentioned as a candidate for nationally prominent positions in scientific administration, Goldstein, like his colleague Michael Brown, chose to continue hands-on research. [8] [9]
In 1993, their postdoctoral trainees, Wang Xiaodong and Michael Briggs, purified the Sterol Regulatory Element-Binding Proteins (SREBPs), a family of membrane-bound transcription factors. Since 1993, Goldstein, Brown, and their colleagues have described the unexpectedly complex machinery that proteolytically releases the SREBPs from membranes, thus allowing their migration to the nucleus where they activate all the genes involved in the synthesis of cholesterol and fatty acids. The machinery for generating active SREBPs is tightly regulated by a negative feedback mechanism, which explains how cells maintain the necessary levels of fats and cholesterol in the face of varying environmental circumstances. [10] [11] [12]
Goldstein is chair, Molecular Genetics at University of Texas Southwestern Medical Center. Together, Goldstein and Brown lead a research team that typically includes a dozen doctoral and postdoctoral trainees. They have trained over 145 graduate students and postdoctoral fellows, and six of their former postdoctoral fellows (Thomas C. Südhof, Wang Xiaodong, Helen H. Hobbs, David W. Russell, Monty Krieger, and Russell DeBose-Boyd) have been elected to the U.S. National Academy of Sciences. [13] Former postdoctoral fellow Thomas C. Südhof received the 2013 Nobel Prize in Medicine or Physiology [14] and Helen H. Hobbs received the 2015 Breakthrough Prize in Life Sciences. [15] [16]
In 1988 Goldstein received a National Medal of Science in the field of molecular genetics, [17] and in 2003 Goldstein and Brown won the Albany Medical Center Prize in Medicine and Biomedical Research in recognition for their further work in understanding cholesterol and also the discovery of an insulin-sensitive regulator, which potentially could be used to develop treatments for diabetes mellitus. [18] Goldstein is a member of the U.S. National Academy of Sciences [19] and the Institute of Medicine [20] and he was elected a Foreign Member of the Royal Society (ForMemRS) in 1991. [21]
Goldstein was appointed as chairman of the Albert Lasker Medical Research Awards jury in 1995, [22] and was a recipient of the award ten years earlier. [23] Since 2000, Goldstein has authored a series of essays on the deep relationship between art and science that appear in the annual Nature Medicine supplement that accompanies the Lasker Awards. [24]
Among his professional activities, Goldstein is a member of the Board of Trustees of The Howard Hughes Medical Institute [25] and of The Rockefeller University, where he was elected as a Life Trustee in 2015. [26] He also serves as chairman of the Board of Scientific Counselors of the Broad Institute, [27] and is a member of the Board of Directors of Regeneron Pharmaceuticals, Inc. [28] He previously served on The Board of Scientific Governors of the Scripps Research Institute, a nonprofit institute that conducts biomedical research. [29]
Joseph L. Goldstein has been awarded the following:
Since 2000, Goldstein has authored a series of essays considering science as a creative pursuit, and explores the links between art and science. The essays have appeared in the journals Nature Medicine, Cell, and most recently, PNAS. They coincide with the annual announcement of the Lasker Awards, with which Goldstein is affiliated in the capacity of jury chairman. A collection of Goldstein's essays titled The Art of Science was published in 2023.
HMG-CoA reductase is the rate-controlling enzyme of the mevalonate pathway, the metabolic pathway that produces cholesterol and other isoprenoids. HMGCR catalyzes the conversion of HMG-CoA to mevalonic acid, a necessary step in the biosynthesis of cholesterol. Normally in mammalian cells this enzyme is competitively suppressed so that its effect is controlled. This enzyme is the target of the widely available cholesterol-lowering drugs known collectively as the statins, which help treat dyslipidemia.
Mario Ramberg Capecchi is an Italian-born molecular geneticist and a co-awardee of the 2007 Nobel Prize in Physiology or Medicine for discovering a method to create mice in which a specific gene is turned off, known as knockout mice. He shared the prize with Martin Evans and Oliver Smithies. He is currently Distinguished Professor of Human Genetics and Biology at the University of Utah School of Medicine.
Michael Stuart Brown ForMemRS NAS AAA&S APS is an American geneticist and Nobel laureate. He was awarded the Nobel Prize in Physiology or Medicine with Joseph L. Goldstein in 1985 for describing the regulation of cholesterol metabolism.
Sir Martin John EvansFLSW is an English biologist who, with Matthew Kaufman, was the first to culture mice embryonic stem cells and cultivate them in a laboratory in 1981. He is also known, along with Mario Capecchi and Oliver Smithies, for his work in the development of the knockout mouse and the related technology of gene targeting, a method of using embryonic stem cells to create specific gene modifications in mice. In 2007, the three shared the Nobel Prize in Physiology or Medicine in recognition of their discovery and contribution to the efforts to develop new treatments for illnesses in humans.
The low-density lipoprotein receptor (LDL-R) is a mosaic protein of 839 amino acids that mediates the endocytosis of cholesterol-rich low-density lipoprotein (LDL). It is a cell-surface receptor that recognizes apolipoprotein B100 (ApoB100), which is embedded in the outer phospholipid layer of very low-density lipoprotein (VLDL), their remnants—i.e. intermediate-density lipoprotein (IDL), and LDL particles. The receptor also recognizes apolipoprotein E (ApoE) which is found in chylomicron remnants and IDL. In humans, the LDL receptor protein is encoded by the LDLR gene on chromosome 19. It belongs to the low density lipoprotein receptor gene family. It is most significantly expressed in bronchial epithelial cells and adrenal gland and cortex tissue.
Sterol regulatory element-binding proteins (SREBPs) are transcription factors that bind to the sterol regulatory element DNA sequence TCACNCCAC. Mammalian SREBPs are encoded by the genes SREBF1 and SREBF2. SREBPs belong to the basic-helix-loop-helix leucine zipper class of transcription factors. Unactivated SREBPs are attached to the nuclear envelope and endoplasmic reticulum membranes. In cells with low levels of sterols, SREBPs are cleaved to a water-soluble N-terminal domain that is translocated to the nucleus. These activated SREBPs then bind to specific sterol regulatory element DNA sequences, thus upregulating the synthesis of enzymes involved in sterol biosynthesis. Sterols in turn inhibit the cleavage of SREBPs and therefore synthesis of additional sterols is reduced through a negative feed back loop.
Akira Endo was a Japanese biochemist whose research into the relationship between fungi and cholesterol biosynthesis led to the development of statin drugs, which are some of the best-selling pharmaceuticals in history.
Carolyn Widney Greider is an American molecular biologist and Nobel laureate. She is a Distinguished Professor of Molecular, Cell, and Developmental Biology at the University of California, Santa Cruz.
Sterol regulatory element-binding protein cleavage-activating protein, also known as SREBP cleavage-activating protein or SCAP, is a protein that in humans is encoded by the SCAP gene.
Xiaodong Wang is a Chinese-American biochemist best known for his work with apoptosis, one of the ways through which cells kill themselves.
Arthur L. Horwich is an American biologist and Sterling Professor of Genetics and Pediatrics at the Yale School of Medicine. Horwich has also been a Howard Hughes Medical Institute investigator since 1990. His research into protein folding uncovered the action of chaperonins, protein complexes that assist the folding of other proteins; Horwich first published this work in 1989.
Sterol regulatory element-binding transcription factor 1 (SREBF1) also known as sterol regulatory element-binding protein 1 (SREBP-1) is a protein that in humans is encoded by the SREBF1 gene.
Sterol regulatory element-binding protein 2 (SREBP-2) also known as sterol regulatory element binding transcription factor 2 (SREBF2) is a protein that in humans is encoded by the SREBF2 gene.
Membrane-bound transcription factor site-2 protease, also known as S2P endopeptidase or site-2 protease (S2P), is an enzyme encoded by the MBTPS2 gene which liberates the N-terminal fragment of sterol regulatory element-binding protein (SREBP) transcription factors from membranes. S2P cleaves the transmembrane domain of SREBP, making it a member of the class of intramembrane proteases.
Insulin induced gene 1, also known as INSIG1, is a protein which in humans is encoded by the INSIG1 gene.
Insulin induced gene 2, also known as INSIG2, is a protein which in humans is encoded by the INSIG2 gene.
Victor R. Ambros is an American developmental biologist and Nobel Laureate who discovered the first known microRNA (miRNA). He is a professor at the University of Massachusetts Medical School. He completed both his undergraduate and doctoral studies at the Massachusetts Institute of Technology. Ambros received the Nobel Prize in Physiology or Medicine in 2024 for his research on microRNA.
Thomas Christian Südhof, ForMemRS, is a German-American biochemist known for his study of synaptic transmission. Currently, he is a professor in the school of medicine in the department of molecular and cellular physiology, and by courtesy in neurology, and in psychiatry and behavioral sciences at Stanford University.
Sandip Kumar Basu is an Indian molecular biologist and the holder of the J. C. Bose Chair of the National Academy of Sciences, India, who is credited with innovations in the treatment protocols of leishmaniasis, tuberculosis, viral infections, multidrug resistant cancer and arterosclerosis. He was honored by the Government of India, in 2001, with the fourth highest Indian civilian award of Padma Shri.
Gregg Leonard Semenza is an American pediatrician and Professor of Genetic Medicine at the Johns Hopkins School of Medicine. He serves as the director of the vascular program at the Institute for Cell Engineering. He is a 2016 recipient of the Albert Lasker Award for Basic Medical Research. He is known for his discovery of HIF-1, which allows cancer cells to adapt to oxygen-poor environments. He shared the 2019 Nobel Prize in Physiology or Medicine for "discoveries of how cells sense and adapt to oxygen availability" with William Kaelin Jr. and Peter J. Ratcliffe. Semenza has had thirteen research papers retracted due to falsified data.